Sinovac Biotech Ltd (SVA) stock
SVANasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.47+0.00 (0.00%)
Close on Nov 13, 2026Market cap $464.94MP/E –Yield 850.08%
Sinovac Biotech total assets
Total assets on the balance sheet at the end of each period.
Sinovac Biotech's total assets was $8.54B at Dec 31, 2025. For fiscal 2025 it was $8.54B, down 30.8% from the year before. Over ten years it grew 45.4% a year on average. The highest annual figure on record is $16.76B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.54B | -30.8% |
| FY2024 | Dec 31, 2024 | $12.34B | -9.4% |
| FY2023 | Dec 31, 2023 | $13.61B | -3.0% |
| FY2022 | Dec 31, 2022 | $14.03B | -16.3% |
| FY2021 | Dec 31, 2021 | $16.76B | +781.4% |
| FY2020 | Dec 31, 2020 | $1.90B | +320.4% |
| FY2019 | Dec 31, 2019 | $452.30M | +22.3% |
| FY2018 | Dec 31, 2018 | $369.78M | +23.6% |
| FY2017 | Dec 31, 2017 | $299.22M | +41.6% |
| FY2016 | Dec 31, 2016 | $211.36M | +4.2% |
| FY2015 | Dec 31, 2015 | $202.93M | -14.9% |
| FY2014 | Dec 31, 2014 | $238.53M | -0.9% |
| FY2013 | Dec 31, 2013 | $240.69M | +15.3% |
| FY2012 | Dec 31, 2012 | $208.76M | -3.3% |
| FY2011 | Dec 31, 2011 | $215.91M | +0.7% |
| FY2010 | Dec 31, 2010 | $214.36M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $8.54B | -49.0% |
| Q4 FY2024 | Dec 31, 2024 | $12.34B | +548.9% |
| Q4 FY2023 | Dec 31, 2023 | $13.61B | +2909.5% |
| Q4 FY2022 | Dec 31, 2022 | $14.03B | +3694.3% |
| Q4 FY2021 | Dec 31, 2021 | $16.76B | +5500.8% |
| Q4 FY2020 | Dec 31, 2020 | $1.90B | +799.6% |
| Q4 FY2019 | Dec 31, 2019 | $452.30M | +122.9% |
| Q4 FY2018 | Dec 31, 2018 | $369.78M | +55.0% |
| Q4 FY2017 | Dec 31, 2017 | $299.22M | +24.3% |
| Q4 FY2016 | Dec 31, 2016 | $211.36M | +1.2% |
| Q4 FY2015 | Dec 31, 2015 | $202.93M | -6.0% |
| Q4 FY2014 | Dec 31, 2014 | $238.53M | +11.3% |
| Q4 FY2013 | Dec 31, 2013 | $240.69M | – |
| Q4 FY2012 | Dec 31, 2012 | $208.76M | – |
| Q4 FY2011 | Dec 31, 2011 | $215.91M | – |
| Q4 FY2010 | Dec 31, 2010 | $214.36M | – |
See a number that looks wrong?